Current treatment recommendations do not fully address residual risk attributable to type 2 diabetes
Despite optimal treatment, patients with type 2 diabetes still have residual risk of cardiovascular disease and microvascular disease.3
Aggressive therapy falls short when it comes to reducing cardiovascular risk
o In the STENO-2 study, intensive therapy reduced the risk of death from cardiovascular disease by 62%; however patients still experienced cardiovascular events.13
Note: This figure illustrates the cumulative incidence of the composite cardiovascular or death endpoint.
Despite treatment with intensive, multifactorial therapy, patients still experienced events; therefore, residual risk remains.13